GCP
ORKA

GSA Capital Partners’s Oruka Therapeutics ORKA Stock Holding History

GSA Capital Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-36,829
Closed -$1.31M – 1857
2021
Q3 		$1.31M Buy
36,829
+25,963
+239% +$959K 0.13% 177
2021
Q2 		$455K Buy
10,866
+3,096
+40% +$129K 0.05% 699
2021
Q1 		$340K Buy
7,770
+3,929
+102% +$206K 0.06% 576
2020
Q4 		$185K Buy
+3,841
New +$191K 0.03% 1013

Other funds holding ORKA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GSA Capital Partners's ORKA Position: Q4 2021 in Review

GSA Capital Partners sold out of Oruka Therapeutics (ORKA) in Q4 2021, closing a stake of 36,829 shares — an estimated $1.31M sold.

GSA Capital Partners first reported a position in ORKA in Q4 2020 and held it in 4 quarters. The position peaked at $1.31M in Q3 2021. 20 funds tracked by Wall St. Rank hold ORKA as of Q4 2021.

  • GSA Capital Partners reported no remaining Oruka Therapeutics position as of Q4 2021 after selling out during the quarter.
  • GSA Capital Partners sold 36,829 Oruka Therapeutics shares in Q4 2021, an estimated $1.31M.
  • GSA Capital Partners first reported a position in Oruka Therapeutics in Q4 2020 and held it in 4 quarters.
  • GSA Capital Partners's Oruka Therapeutics position peaked at $1.31M in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.